Capital One Financial Comments on Chimerix, Inc.’s Q2 2024 Earnings (NASDAQ:CMRX)

Chimerix, Inc. (NASDAQ:CMRX) – Capital One Financial issued their Q2 2024 earnings per share (EPS) estimates for Chimerix in a research report issued on Wednesday, May 1st. Capital One Financial analyst N. Quibria expects that the biopharmaceutical company will post earnings per share of ($0.27) for the quarter. The consensus estimate for Chimerix’s current full-year earnings is ($0.81) per share. Capital One Financial also issued estimates for Chimerix’s Q3 2024 earnings at ($0.28) EPS, Q4 2024 earnings at $0.05 EPS, FY2024 earnings at ($0.74) EPS, FY2025 earnings at ($1.10) EPS, FY2026 earnings at ($0.62) EPS and FY2027 earnings at ($0.56) EPS.

CMRX has been the topic of several other research reports. HC Wainwright reiterated a “buy” rating and issued a $11.00 price target on shares of Chimerix in a research note on Friday, March 1st. StockNews.com lowered Chimerix from a “hold” rating to a “sell” rating in a research note on Friday. Finally, Wedbush reissued an “outperform” rating and set a $6.00 price objective on shares of Chimerix in a report on Monday, February 12th.

Chimerix Trading Up 4.9 %

Shares of NASDAQ CMRX opened at $1.00 on Monday. The firm has a market cap of $89.63 million, a P/E ratio of -1.08 and a beta of 1.13. Chimerix has a 1-year low of $0.88 and a 1-year high of $1.57. The business’s 50 day moving average is $1.04 and its 200-day moving average is $1.00.

Chimerix (NASDAQ:CMRX) last announced its earnings results on Wednesday, May 1st. The biopharmaceutical company reported ($0.25) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.04). Chimerix had a negative return on equity of 41.32% and a negative net margin of 25,337.96%. During the same period in the prior year, the business posted ($0.24) EPS.

Hedge Funds Weigh In On Chimerix

Large investors have recently bought and sold shares of the company. Vance Wealth Inc. bought a new position in Chimerix in the fourth quarter valued at about $46,000. Pale Fire Capital SE bought a new position in Chimerix in the third quarter valued at about $95,000. Assenagon Asset Management S.A. increased its stake in shares of Chimerix by 167.3% in the third quarter. Assenagon Asset Management S.A. now owns 426,672 shares of the biopharmaceutical company’s stock valued at $410,000 after buying an additional 267,044 shares during the period. Bank of New York Mellon Corp increased its stake in shares of Chimerix by 190.0% in the third quarter. Bank of New York Mellon Corp now owns 591,697 shares of the biopharmaceutical company’s stock valued at $568,000 after buying an additional 387,638 shares during the period. Finally, Vestal Point Capital LP acquired a new stake in shares of Chimerix in the fourth quarter valued at about $1,348,000. 45.42% of the stock is currently owned by institutional investors.

About Chimerix

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.